Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB) Share Price

Price 650.00p on 16-12-2025 at 14:20:05
Change 10.00p 1.56%
Buy 670.00p
Sell 630.00p
Last Trade: Sell 47.00 at 632.66p
Day's Volume: 6,322
Last Close: 640.00p
Open: 640.00p
ISIN: GB00BMCLYF79
Day's Range 640.00p - 650.00p
52wk Range: 640.00p - 1,250.00p
Market Capitalisation: £100.65m
VWAP: 638.98656p
Shares in Issue: 15.48m

4basebio Plc (4BB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 47 632.66p Ordinary
13:54:31 - 16-Dec-25
Buy* 117 646.00p Ordinary
11:35:03 - 16-Dec-25
Buy* 385 646.00p Ordinary
11:33:38 - 16-Dec-25
Unknown* 1,500 650.00p Ordinary
11:06:17 - 16-Dec-25
Buy* 541 646.00p Ordinary
11:05:15 - 16-Dec-25
Unknown* 3,232 630.00p Negotiated Trade
11:05:09 - 16-Dec-25
Buy* 500 650.00p Ordinary
08:03:47 - 16-Dec-25
Sell* 300 650.00p Ordinary
15:28:54 - 15-Dec-25
Unknown* 500 650.00p Ordinary
13:08:38 - 15-Dec-25
Sell* 73 650.20p Ordinary
12:39:42 - 15-Dec-25
See more 4basebio Plc trades

4basebio Plc (4BB) Share Price History

Time period:
to
Date Open High Low Close Volume
16th Dec 2025 (Tue) 640.00 650.00 640.00 640.00 6,322
15th Dec 2025 (Mon) 687.50 687.50 640.00 640.00 1,960
12th Dec 2025 (Fri) 690.00 690.00 687.50 687.50 2,500
11th Dec 2025 (Thu) 695.00 695.00 690.00 690.00 1,627
10th Dec 2025 (Wed) 712.50 712.50 695.00 695.00 269
9th Dec 2025 (Tue) 712.50 712.50 712.50 712.50 9
8th Dec 2025 (Mon) 712.50 712.50 712.50 712.50 8,658
5th Dec 2025 (Fri) 712.50 712.50 712.50 712.50 6
4th Dec 2025 (Thu) 712.50 712.50 712.50 712.50 1,233
3rd Dec 2025 (Wed) 712.50 712.50 712.50 712.50 0
2nd Dec 2025 (Tue) 712.50 712.50 712.50 712.50 144
1st Dec 2025 (Mon) 712.50 712.50 712.50 712.50 0
28th Nov 2025 (Fri) 712.50 712.50 712.50 712.50 51
27th Nov 2025 (Thu) 712.50 712.50 712.50 712.50 14
26th Nov 2025 (Wed) 712.50 712.50 712.50 712.50 15
25th Nov 2025 (Tue) 712.50 712.50 712.50 712.50 588
24th Nov 2025 (Mon) 725.00 715.00 712.50 712.50 70
21st Nov 2025 (Fri) 712.50 712.50 712.50 712.50 11
20th Nov 2025 (Thu) 712.50 712.50 650.00 712.50 1,590
19th Nov 2025 (Wed) 712.50 712.50 712.50 712.50 1,080
18th Nov 2025 (Tue) 712.50 712.50 712.50 712.50 0
17th Nov 2025 (Mon) 712.50 712.50 712.50 712.50 0
See more 4basebio Plc price history

4basebio Plc (4BB) Regulatory News

Date Source Headline
27th Oct 2025 7:00 am PRN Synthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 2025 11:30 am PRN Result of Extraordinary General Meeting
30th Sep 2025 4:20 pm PRN Director Dealing
29th Sep 2025 7:00 am PRN Half-year Report
22nd Jul 2025 7:00 am PRN Employee Long Term Incentive Plan and Issue of Equity
8th Jul 2025 10:30 am PRN Director Appointment, Board Change
3rd Jul 2025 7:00 am PRN Holding(s) in Company
3rd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
See more 4basebio Plc regulatory news

4basebio Plc (4BB) Share News

4basebio says "tier one" partner tests vaccine from its template

27th Oct 2025 12:40

(Alliance News) - 4basebio PLC on Monday said its synthetic DNA product has been used in US clinical trials by a "global tier one" pharmaceutical partner. Read More

EARNINGS: Next 15 profit falls; 4basebio and Mollyroe losses widen

1st Oct 2025 12:57

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

20th Jun 2025 12:02

Read More

4basebio expects to sustain DNA sales growth momentum in 2025

27th May 2025 11:57

(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More

IN BRIEF: 4basebio hits "critical milestone" as it secures GMP licence

2nd Apr 2025 09:51

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More

See more 4basebio Plc news
FTSE 100 Latest
Value9,682.16
Change-69.15

Login to your account

Forgot Password?

Not Registered